Results 231 to 240 of about 738,044 (342)
Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma
Vignesh Shanmugam +5 more
semanticscholar +1 more source
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons +17 more
wiley +1 more source
AVN944 Elicits Apoptotic Responses and Impedes Tumorigenic Potential in Ewing's Sarcoma Cells. [PDF]
Lim H, Lee S, Kim G, Lee EJ, Kim J.
europepmc +1 more source
Linking the NETSARC+ National Sarcoma Database With the SNDS to Evaluate Adjuvant and/or Neoadjuvant Therapy: Report on the Linkage Process and Result (Health Data Hub's DEEPSARC Pilot Project). [PDF]
Drezen E +12 more
europepmc +1 more source
An aggressive soft-tissue sarcoma of the extremity: A myxofibrosarcoma, grade 3 (FNCLCC system)
Manuela Montatore +6 more
openalex +1 more source
Improved survival using specialized multidisciplinary board in sarcoma patients
Jean-Yves Blay +29 more
semanticscholar +1 more source
Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma
ABSTRACT Purpose Olfactory neuroblastoma (ONB) is a rare sinonasal malignancy with limited therapeutic options in the recurrent/metastatic setting; little is known regarding its responsiveness to immunotherapy. Inhibition of enhancer of zeste homolog 2 (EZH2) has been shown to improve T‐cell‐mediated killing and susceptibility to immune checkpoint ...
Elisabetta Xue +12 more
wiley +1 more source
DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma
Nathan C. Sheffield +37 more
semanticscholar +1 more source

